471 related articles for article (PubMed ID: 26444865)
21. Platinum sensitivity in metastatic prostate cancer: does histology matter?
Humeniuk MS; Gupta RT; Healy P; McNamara M; Ramalingam S; Harrison M; George D; Zhang T; Wu Y; Armstrong AJ
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):92-99. PubMed ID: 29230006
[TBL] [Abstract][Full Text] [Related]
22. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
[No Abstract] [Full Text] [Related]
23. Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer.
Huang G; Zhang H; Shi H; Zhang W; Wang T; Wang Z; Chen Q; Lian B; Li J; Yang G
World J Surg Oncol; 2022 Dec; 20(1):407. PubMed ID: 36572885
[TBL] [Abstract][Full Text] [Related]
24. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis.
Wang HT; Yao YH; Li BG; Tang Y; Chang JW; Zhang J
J Clin Oncol; 2014 Oct; 32(30):3383-90. PubMed ID: 25225419
[TBL] [Abstract][Full Text] [Related]
25. Association of intraductal carcinoma of the prostate detected by initial histological specimen and neuroendocrine prostate cancer: A report of three cases.
Ikeda J; Ohe C; Ohsugi H; Matsuda T; Tsuta K; Kinoshita H
Pathol Int; 2021 Sep; 71(9):621-626. PubMed ID: 34297443
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis and management of neuroendocrine prostate cancer.
de Kouchkovsky I; Chan E; Schloss C; Poehlein C; Aggarwal R
Prostate; 2024 Apr; 84(5):426-440. PubMed ID: 38173302
[TBL] [Abstract][Full Text] [Related]
27. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.
Young G; Wang K; He J; Otto G; Hawryluk M; Zwirco Z; Brennan T; Nahas M; Donahue A; Yelensky R; Lipson D; Sheehan CE; Boguniewicz AB; Stephens PJ; Miller VA; Ross JS
Cancer Cytopathol; 2013 Dec; 121(12):688-94. PubMed ID: 23893923
[TBL] [Abstract][Full Text] [Related]
28. Alternative RNA splicing of the GIT1 gene is associated with neuroendocrine prostate cancer.
Lee AR; Gan Y; Xie N; Ramnarine VR; Lovnicki JM; Dong X
Cancer Sci; 2019 Jan; 110(1):245-255. PubMed ID: 30417466
[TBL] [Abstract][Full Text] [Related]
29. Case Report: Systemic Treatment and Serial Genomic Sequencing of Metastatic Prostate Adenocarcinoma Progressing to Small Cell Carcinoma.
Lu X; Gao W; Zhang Y; Wang T; Gao H; Chen Q; Shi X; Lian B; Zhang W; Gao X; Li J
Front Oncol; 2021; 11():732071. PubMed ID: 34646773
[TBL] [Abstract][Full Text] [Related]
30. Review of Checkpoint Inhibitor Immunotherapy in Neuroendocrine Tumor of Prostate and Our Experience in 2 Cases.
Pokhrel A; Nair K; Jaswani V; Salyana M; Mooppan U; Wang JC
J Investig Med High Impact Case Rep; 2022; 10():23247096221093886. PubMed ID: 35473437
[TBL] [Abstract][Full Text] [Related]
31. Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma.
Ostano P; Mello-Grand M; Sesia D; Gregnanin I; Peraldo-Neia C; Guana F; Jachetti E; Farsetti A; Chiorino G
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32041153
[TBL] [Abstract][Full Text] [Related]
32. Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer.
Lin D; Dong X; Wang K; Wyatt AW; Crea F; Xue H; Wang Y; Wu R; Bell RH; Haegert A; Brahmbhatt S; Hurtado-Coll A; Gout PW; Fazli L; Gleave ME; Collins CC; Wang Y
Oncotarget; 2015 Jan; 6(3):1806-20. PubMed ID: 25544761
[TBL] [Abstract][Full Text] [Related]
33. Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy.
Miyoshi Y; Uemura H; Kitami K; Satomi Y; Kubota Y; Hosaka M
BJU Int; 2001 Dec; 88(9):982-3. PubMed ID: 11851626
[No Abstract] [Full Text] [Related]
34. Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13.
Okasho K; Mizuno K; Fukui T; Lin YY; Kamiyama Y; Sunada T; Li X; Kimura H; Sumiyoshi T; Goto T; Kobayashi T; Lin D; Wang Y; Collins CC; Inoue T; Ogawa O; Akamatsu S
Cancer Sci; 2021 Jul; 112(7):2781-2791. PubMed ID: 33960594
[TBL] [Abstract][Full Text] [Related]
35. Preclinical Models of Neuroendocrine Prostate Cancer.
Cacciatore A; Albino D; Catapano CV; Carbone GM
Curr Protoc; 2023 May; 3(5):e742. PubMed ID: 37166213
[TBL] [Abstract][Full Text] [Related]
36. Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review.
Uehara R; Obinata D; Hashimoto S; Nakahara K; Uchida H; Yoshizawa T; Mochida J; Yamaguchi K; Sakaguchi M; Ozawa Y; Mori F; Miura K; Ishige T; Masuda S; Nakayama T; Takahashi S
Medicine (Baltimore); 2024 Mar; 103(9):e37371. PubMed ID: 38428891
[TBL] [Abstract][Full Text] [Related]
37. ONECUT2 is a driver of neuroendocrine prostate cancer.
Guo H; Ci X; Ahmed M; Hua JT; Soares F; Lin D; Puca L; Vosoughi A; Xue H; Li E; Su P; Chen S; Nguyen T; Liang Y; Zhang Y; Xu X; Xu J; Sheahan AV; Ba-Alawi W; Zhang S; Mahamud O; Vellanki RN; Gleave M; Bristow RG; Haibe-Kains B; Poirier JT; Rudin CM; Tsao MS; Wouters BG; Fazli L; Feng FY; Ellis L; van der Kwast T; Berlin A; Koritzinsky M; Boutros PC; Zoubeidi A; Beltran H; Wang Y; He HH
Nat Commun; 2019 Jan; 10(1):278. PubMed ID: 30655535
[TBL] [Abstract][Full Text] [Related]
38. RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.
Li Y; Xie N; Chen R; Lee AR; Lovnicki J; Morrison EA; Fazli L; Zhang Q; Musselman CA; Wang Y; Huang J; Gleave ME; Collins C; Dong X
Eur Urol; 2019 Aug; 76(2):157-166. PubMed ID: 30910347
[TBL] [Abstract][Full Text] [Related]
39. Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma.
Sulsenti R; Frossi B; Bongiovanni L; Cancila V; Ostano P; Fischetti I; Enriquez C; Guana F; Chiorino G; Tripodo C; Pucillo CE; Colombo MP; Jachetti E
Front Immunol; 2021; 12():622001. PubMed ID: 33737929
[TBL] [Abstract][Full Text] [Related]
40. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
Baca SC; Takeda DY; Seo JH; Hwang J; Ku SY; Arafeh R; Arnoff T; Agarwal S; Bell C; O'Connor E; Qiu X; Alaiwi SA; Corona RI; Fonseca MAS; Giambartolomei C; Cejas P; Lim K; He M; Sheahan A; Nassar A; Berchuck JE; Brown L; Nguyen HM; Coleman IM; Kaipainen A; De Sarkar N; Nelson PS; Morrissey C; Korthauer K; Pomerantz MM; Ellis L; Pasaniuc B; Lawrenson K; Kelly K; Zoubeidi A; Hahn WC; Beltran H; Long HW; Brown M; Corey E; Freedman ML
Nat Commun; 2021 Mar; 12(1):1979. PubMed ID: 33785741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]